HDL Nomenclature Self-Study Slide Library Activity


HDL Nomenclature Self-Study Slide Library Activity

Topic: Cardiology
Relevant Terms: HDL Classification And Nomenclature
Primary Audience: Cardiologists; Physicians; Clinicians; Specialist Health Care Providers
Launch Date: 10-Sep-12
Credits: 1.25 AMA PRA Category 1 Credits
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Review the metabolic pathways that regulate HDL and describe the associations between certain HDL subclasses and CVD risk.
  2. Describe the new nomenclature of HDL particles based on the physicochemical characteristics of HDL lipoproteins.


    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Director, Cardiometabolic Disorders
    Mount Sinai Heart
    Professor of Medicine
    Mount Sinai School of Medicine
    New York, NY
    H. Bryan Brewer, Jr., MD, FNLA
    Director, Washington Cardiovascular Associates
    Senior Research Consultant
    Lipoprotein and Atherosclerosis Research
    MedStar Research Institute
    Washington Hospital Center
    Washington, DC
    Welcome! Please review the following CME information for this activity and click "Proceed to Course" to enter the activity.

    CME Information
    Release date: September 2012
    Expiration date: September 2013
    Estimated time to complete activity: 1.25 hours
    System requirements: Any modern web browser that supports Flash is required to view the video content for this activity. High-speed Internet access also is recommended. This activity cannot be viewed with iOS devices (iPhones, iPads) at this time.

    Target Audience
    This activity has been designed to meet the educational needs of cardiologists and other physicians, clinicians, and specialist heath care providers involved in the treatment of patients with lipid disorders and cardiovascular disease.

    Program Overview
    According to current standards of care and guidelines, residual risk of vascular events persists even in patients who are at treatment goals. Traditionally, reducing LDL-C has been the primary target of cardiovascular disease (CVD) prevention. However, there is increasing attention on high-density lipoprotein cholesterol (HDL-C) as a secondary prevention target to address residual cardiovascular risk. Low HDL-C is widely prevalent in Westernized countries and is independently predictive of CVD, even in patients with low levels of LDL-C.

    Levels of HDL-C are associated inversely with cardiovascular risk; however, cholesterol is carried in a heterogeneous class of HDL particles. Despite the substantial epidemiological data demonstrating the "cardioprotective" role of HDL, much remains unknown about the multifarious anti-atherogenic properties of HDL. Multiple analytical methods have been developed to quantify HDL subclasses and investigate CVD risk associations in prospective population studies and clinical trials of lipid-modifying therapy. The association of specific HDL subclasses with atherosclerosis and cardiovascular events has been used to suggest that certain HDL functions associated with that HDL subclass are more important in a particular population or with a certain HDL-modifying intervention. The "validation" of HDL biomarkers has been used in the evaluation of novel HDL-modifying therapies. Because multiple analytical methods have been used to quantify HDL, it is important to categorize HDL nomenclature using common physical and chemical properties. It is paramount that physicians caring for patients with CVD continue to receive education from lead researchers and clinicians in order to interpret the latest findings, implement best practices, and maximize patient outcomes.

    This activity will provide streamlined access to key information related to advances in HDL science through the HDL nomenclature slide library and video overview. The slides in this self-study contain key data and evidence-based findings of pre-clinical and clinical trials in the field of HDL science, and the slide notes provide concise summaries of key learning points.

    Program Agenda
    HDL Nomenclature Self-Study Activity
    is a part of the Academy for the Advancement of HDL Science continuing educational series.

    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    H. Bryan Brewer, Jr., MD

    This activity consists of a video overview on HDL nomenclature and didactic slides organized into 5 topical chapters, primarily focusing on HDL-C and cardiovascular risk, analytical limitations of HDL-C measurements, and classification of HDL by lipoprotein particles based on apolipoprotein composition and proposed nomenclature. Slides with notes will be accessible as printable PDFs to further learning.


    Method of Participation
    There are no fees for participating in and receiving CME credit for this activity. During the period August 2012 through August 2013, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest, and 4) complete the evaluation form.

    A statement of credit will be issued only upon electronic submission of a completed activity evaluation form and a completed posttest with a score of 70% or better. Statements of credit should be printed online upon completion via the NLA website.

    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications (CMC). MER is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation for HDL Nomenclature Self-Study Activity
    Medical Education Resources designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    To contact Medical Education Resources, please call 303-798-9682.

    Disclosure of Conflicts of Interest
    Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.

    The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

    Name of Faculty
    Reported Financial Relationship
    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Grants/research support from Amgen, Genentech, Roche, and Sanofi Aventis; consulting fees from Abbott Laboratories, Amgen, Genentech, LipoScience, Roche, and Sanofi Aventis; and ownership interest/shareholder in LipoScience
    H. Bryan Brewer, Jr., MD
    Consulting fees from and speakers' bureau participant with AstraZeneca, Lilly, Merck, Pfizer, and Roche; ownership interest/shareholder in HDL Therapeutics and The Medicines Company; and royalty/patent holder with HDL Therapeutics

    The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

    Name of Content Manager
    Reported Financial Relationship
    Jennifer Frederick, PharmD, BCPS
    No financial relationships to disclose
    Julie Johnson, PharmD
    No financial relationships to disclose

    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Consensus Medical Communications (CMC), or Genentech. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, CMC, and Genentech. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

    Medical Education Resources Privacy Policy
    Medical Education Resources and Consensus Medical Communications maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.

    The only information Medical Education Resources obtains is information supplied voluntarily by the visitor.

    We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.

    We use the information to grade your posttest and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.

    For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

    We may use the information to invite you to participate in other CME activities that we may offer.

    On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity in order to document the first level of outcomes-based evaluation in CME (eg, who attended, which medical specialties/practices were represented, how this compares with the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will request in writing that the supporter not contact you directly for any purpose.

    Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us at info@cmepartner.org.

    This activity is jointly sponsored by Medical Education Resources and Consensus Medical Communications.

    Commercial Support
    This activity is supported by an educational grant from Genentech.